RESUMEN
Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterized by recurrent nodules, abscesses, and sinus tracts, resulting in scarring. Patients suffer significantly impacted quality of life (QoL), manifested by anxiety and depression. We describe microbial isolates identified from active sites in adults with HS, and explore associations between organisms isolated, disease severity, and QoL. Methods: Observational study over 2 years. Assessment was made of disease severity using the Hurley staging score and of QoL scores, and subjective assessment. Wound swab samples were obtained from sites of active disease. Descriptive summary statistics and tests of significance were used to analyse the data. Results: Two hundred and twelve patients participated, resulting in 352 episodes, and 501 lesion swab samples. 54% were female and 59% were obese, median age of 37 years. A lower proportion of Gram-negative organisms and more staphylococcal and streptococcal organisms were isolated from sites of disease in individuals with stage 3 disease compared to those with stage 1-2 disease (p = 0.001). We found no association between microbial isolation and QoL. Discussion/Conclusions: Hurley stage 3 disease is associated with more infected lesions than Hurley stage 1-2 disease, but the QoL experienced by patients with HS is determined by factors other than infection.
RESUMEN
We describe a case of hemorrhagic fever with renal syndrome caused by Seoul virus in a woman in Scotland, UK. Whole-genome sequencing showed the virus belonged to a lineage characterized by recent international expansion, probably driven by trade in pet rats.
Asunto(s)
Fiebre Hemorrágica con Síndrome Renal , Virus Seoul , Animales , Fiebre Hemorrágica con Síndrome Renal/diagnóstico , Humanos , Riñón , Ratas , Escocia/epidemiología , Virus Seoul/genética , Reino UnidoRESUMEN
BACKGROUND: Development of an effective vaccine against the pathogenic blood-stage infection of human malaria has proved challenging, and no candidate vaccine has affected blood-stage parasitemia following controlled human malaria infection (CHMI) with blood-stage Plasmodium falciparum. METHODS: We undertook a phase I/IIa clinical trial in healthy adults in the United Kingdom of the RH5.1 recombinant protein vaccine, targeting the P. falciparum reticulocyte-binding protein homolog 5 (RH5), formulated in AS01B adjuvant. We assessed safety, immunogenicity, and efficacy against blood-stage CHMI. Trial registered at ClinicalTrials.gov, NCT02927145. FINDINGS: The RH5.1/AS01B formulation was administered using a range of RH5.1 protein vaccine doses (2, 10, and 50 µg) and was found to be safe and well tolerated. A regimen using a delayed and fractional third dose, in contrast to three doses given at monthly intervals, led to significantly improved antibody response longevity over â¼2 years of follow-up. Following primary and secondary CHMI of vaccinees with blood-stage P. falciparum, a significant reduction in parasite growth rate was observed, defining a milestone for the blood-stage malaria vaccine field. We show that growth inhibition activity measured in vitro using purified immunoglobulin G (IgG) antibody strongly correlates with in vivo reduction of the parasite growth rate and also identify other antibody feature sets by systems serology, including the plasma anti-RH5 IgA1 response, that are associated with challenge outcome. CONCLUSIONS: Our data provide a new framework to guide rational design and delivery of next-generation vaccines to protect against malaria disease. FUNDING: This study was supported by USAID, UK MRC, Wellcome Trust, NIAID, and the NIHR Oxford-BRC.
Asunto(s)
Vacunas contra la Malaria , Malaria Falciparum , Malaria , Adulto , Humanos , Malaria/inducido químicamente , Vacunas contra la Malaria/uso terapéutico , Malaria Falciparum/prevención & control , Plasmodium falciparum , Vacunación , Vacunas SintéticasRESUMEN
COVID-19 led to the widespread withdrawal of face-to-face hospital-based clinical placements, with many medical schools switching to online learning. This precipitated concern about potential negative impact on clinical and interprofessional skill acquisition. To overcome this problem, we piloted a 12-week COVID-19 safe face-to-face clinical placement for 16 medical students at the Hospital for Tropical Diseases, London, during the first wave of the COVID-19 pandemic. COVID-19 infection control measures necessitated that students remained in 'social bubbles' for placement duration. This facilitated an apprenticeship-style teaching approach, integrating students into the clinical team for placement duration. Team-based learning was adopted to develop and deliver content. Teaching comprised weekly seminars, experiential ward-based attachments and participation in quality improvement and research projects. The taught content was evaluated through qualitative feedback, reflective practice, and pre-apprenticeship and post-apprenticeship confidence questionnaires across 17 domains. Students' confidence improved in 14 of 17 domains (p<0.05). Reflective practice indicated that students valued the apprenticeship model, preferring the longer clinical attachment to existent shorter, fragmented clinical placements. Students described improved critical thinking, group cohesion, teamwork, self-confidence, self-worth and communication skills. This article describes a framework for the safe and effective delivery of a longer face-to-face apprenticeship-based clinical placement during an infectious disease pandemic. Longer apprenticeship-style attachments have hidden benefits to general professional training, which should be explored by medical schools both during the COVID-19 pandemic and, possibly, for any future clinical placements.
Asunto(s)
COVID-19 , Prácticas Clínicas , Competencia Clínica , Educación de Pregrado en Medicina , Enseñanza , COVID-19/epidemiología , COVID-19/prevención & control , Prácticas Clínicas/métodos , Prácticas Clínicas/tendencias , Educación a Distancia , Educación de Pregrado en Medicina/métodos , Educación de Pregrado en Medicina/organización & administración , Hospitales de Enseñanza/organización & administración , Humanos , Control de Infecciones/métodos , Educación Interprofesional , Londres , Mejoramiento de la Calidad , SARS-CoV-2 , Estudiantes de Medicina , Enseñanza/normas , Enseñanza/tendenciasAsunto(s)
Antibacterianos/administración & dosificación , Endocarditis Bacteriana/tratamiento farmacológico , Endocarditis Bacteriana/microbiología , Infecciones por Pseudomonas/tratamiento farmacológico , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa , Quimioterapia Combinada , Femenino , Humanos , Infusiones Parenterales , Pacientes Ambulatorios , Diálisis Renal , Resultado del TratamientoAsunto(s)
Técnicas Microbiológicas/estadística & datos numéricos , Pericarditis/diagnóstico , Pautas de la Práctica en Medicina/estadística & datos numéricos , Análisis Costo-Beneficio , Humanos , Técnicas Microbiológicas/economía , Pericarditis/microbiología , Guías de Práctica Clínica como Asunto , Estudios Retrospectivos , Reino UnidoAsunto(s)
Celulitis (Flemón)/diagnóstico , Celulitis (Flemón)/tratamiento farmacológico , Erisipela/diagnóstico , Erisipela/tratamiento farmacológico , Antiinfecciosos/administración & dosificación , Celulitis (Flemón)/epidemiología , Celulitis (Flemón)/etiología , Erisipela/epidemiología , Erisipela/etiología , HumanosRESUMEN
Stanozolol is a popular androgenic anabolic steroid, used by body builders and athletes for physical performance enhancement. There are few data on its potential adverse effects and no documented cases of it causing severe electrolyte imbalance. Here, we report a patient presenting to a tertiary care emergency department with reduced conscious level, profound hypokalemia, and severe metabolic alkalosis, resulting from stanozolol misuse. This is the first such case reported.
Asunto(s)
Alcalosis/inducido químicamente , Anabolizantes/efectos adversos , Hipopotasemia/inducido químicamente , Estanozolol/efectos adversos , Trastornos Relacionados con Sustancias/complicaciones , Enfermedad Aguda , Adulto , Humanos , MasculinoRESUMEN
Influenza is a seasonal, viral, respiratory tract infection, presenting as a febrile illness with associated systemic upset. It causes biannual epidemics and occasional global pandemics. Diagnosis is made clinically with the assistance of real time polymerase chain reaction of nasopharyngeal swab specimens, and treatment is primarily aimed at symptom control.
Asunto(s)
Gripe Humana , Pandemias , Antivirales/uso terapéutico , Personal de Salud , Humanos , Gripe Humana/tratamiento farmacológico , VirosisRESUMEN
OBJECTIVES: Ovale malaria is caused by two closely related species of protozoan parasite: Plasmodium ovale curtisi and Plasmodium ovale wallikeri Although clearly distinct genetically, there have been no studies comparing the morphology, life cycle or epidemiology of these parasites. We tested the hypothesis that the two species differ in the duration of latency prior to presentation with symptoms of blood-stage infection. DESIGN: PCR was used to identify P ovale curtisi and P ovale wallikeri infections among archived blood from UK malaria patients. Latency periods, estimated as the time between entry into the UK and diagnosis of malaria, were compared between the two groups. SETTING: UK National Reference Laboratory. PARTICIPANTS: None. Archived parasite material and surveillance data for 74 P ovale curtisi and 60 P ovale wallikeri infections were analysed. Additional epidemiological data were taken from a database of 1045 imported cases. OUTCOMES: None. RESULTS: No differences between the two species were identified by a detailed comparison of parasite morphology (N=9, N=8, respectively) and sex ratio (N=5, N=4) in archived blood films. The geometric mean latency period in P ovale wallikeri was 40.6 days (95% CI 28.9 to 57.0), whereas that for P ovale curtisi was more than twice as long at 85.7 days (95% CI 66.1 to 111.1; p=0.002). Further, the proportion of ovale malaria sensu lato which occurred in patients reporting chemoprophylaxis use was higher than for Plasmodium falciparum (OR 7.56; p<0.0001) or P vivax (OR 1.82; p<0.0001). CONCLUSIONS: These findings provide the first difference of epidemiological significance observed between the two parasites which cause ovale malaria, and suggest that control measures aimed at P falciparum may not be adequate for reducing the burden of malaria caused by P ovale curtisi and P ovale wallikeri.